Antiobesity carbonic anhydrase inhibitors

Area of Science:

• Biochemistry
• Pharmacology
• Medicinal Chemistry

Background:

• Obesity is a widespread disease with limited pharmacological treatments.
• Novel therapeutic strategies targeting distinct mechanisms are urgently needed.
• Carbonic anhydrases (CAs) are implicated in lipogenesis, presenting a potential therapeutic target.

Purpose of the Study:

• To investigate the potential of carbonic anhydrase inhibition as a novel approach for obesity treatment.
• To explore the mechanism of weight loss induced by topiramate and zonisamide.
• To identify and synthesize new carbonic anhydrase inhibitors for anti-obesity drug development.

Main Methods:

• Kinetic studies in solution to assess CA inhibitory activity.
• X-ray crystallography to determine drug-enzyme interactions.
• Lipogenesis inhibition assays in adipocytes.
• Synthesis and screening of novel sulfonamide-based CA inhibitors.

Main Results:

• Topiramate and zonisamide exhibit potent inhibition against physiologically relevant carbonic anhydrase isoforms (CA II, VA, VB).
• Topiramate demonstrated inhibition of lipogenesis in adipocytes, consistent with CA inhibition.
• A series of novel sulfonamides were synthesized and evaluated for CA inhibitory properties.

Conclusions:

• Carbonic anhydrase inhibition represents a promising new strategy for the treatment and prophylaxis of obesity.
• Topiramate and zonisamide possess significant CA inhibitory activity, potentially explaining their weight-loss effects.
• Further development of CA inhibitors could lead to new, effective anti-obesity medications.